2015
The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States
Girouard MP, Sax PE, Parker RA, Taiwo B, Freedberg KA, Gulick RM, Weinstein MC, Paltiel AD, Walensky RP. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States. Clinical Infectious Diseases 2015, 62: 784-791. PMID: 26658053, PMCID: PMC4772845, DOI: 10.1093/cid/civ981.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioStandard of careVirologic suppressionART costsBudget impactHuman immunodeficiency virus (HIV) treatmentART-naive patientsDTG/ABC/3TCVirologic suppression ratesSubsequent virologic failureCost-effectiveness ratioPerson/yearInitial regimenAntiretroviral therapyInduction regimenNaive patientsVirologic failureAntiretroviral agentsDual therapyHIV infectionTwo-drugDolutegravirVirus treatmentRegimenSurvival rateThe Clinical Role and Cost-Effectiveness of Long-Acting Antiretroviral Therapy
Ross EL, Weinstein MC, Schackman BR, Sax PE, Paltiel AD, Walensky RP, Freedberg KA, Losina E. The Clinical Role and Cost-Effectiveness of Long-Acting Antiretroviral Therapy. Clinical Infectious Diseases 2015, 60: 1102-1110. PMID: 25583979, PMCID: PMC4366583, DOI: 10.1093/cid/ciu1159.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveCohort StudiesComputer SimulationCost-Benefit AnalysisDelayed-Action PreparationsFemaleHIV InfectionsHumansMaleMiddle AgedSurvival AnalysisTreatment OutcomeConceptsDaily ART adherenceAnnual drug costsART adherenceLA-ARTAntiretroviral therapyDrug costsART-naive patientsDaily oral ARTHIV RNA suppressionSecond-line therapyFirst-line therapyFirst-line regimensHuman immunodeficiency virusDaily ARTOverall life expectancyHIV patientsAdherent patientsAvailable regimensART failureImmunodeficiency virusClinical rolePatientsRNA suppressionTherapyAnnual cost
2014
Clinical Impact and Cost-Effectiveness of Making Third-Line Antiretroviral Therapy Available in Sub-Saharan Africa
Ouattara EN, Ross EL, Yazdanpanah Y, Wong AY, Robine M, Losina E, Moh R, Walensky RP, Danel C, Paltiel AD, Eholié SP, Freedberg KA, Anglaret X. Clinical Impact and Cost-Effectiveness of Making Third-Line Antiretroviral Therapy Available in Sub-Saharan Africa. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2014, 66: 294-302. PMID: 24732870, PMCID: PMC4146647, DOI: 10.1097/qai.0000000000000166.Peer-Reviewed Original ResearchConceptsThird-line antiretroviral therapySecond-line antiretroviral therapyIncremental cost-effectiveness ratioAntiretroviral therapyAdherence reinforcementClinical impactSecond-line ART failureLifetime incremental cost-effectiveness ratioRaltegravir-based regimenSecond-line regimenTen-year survivalSubstantial survival benefitCost-effectiveness ratioPrimary outcomeSurvival benefitART failureDrug costsImmediate switchRegimenPatientsTherapyReinforcement interventionSaharan AfricaSurvivalSub-Saharan Africa
2013
The Survival Benefits of Antiretroviral Therapy in South Africa
April MD, Wood R, Berkowitz BK, Paltiel AD, Anglaret X, Losina E, Freedberg KA, Walensky RP. The Survival Benefits of Antiretroviral Therapy in South Africa. The Journal Of Infectious Diseases 2013, 209: 491-499. PMID: 24307741, PMCID: PMC3903379, DOI: 10.1093/infdis/jit584.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnalysis of VarianceAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountComputer SimulationCost-Benefit AnalysisFemaleHIV InfectionsHumansMaleMiddle AgedModels, TheoreticalSouth AfricaViral LoadConceptsSecond-line antiretroviral therapyAntiretroviral therapySurvival benefitAIDS Complications-International modelTotal survival benefitT-cell countsHuman immunodeficiency virusART initiationART rolloutUntreated patientsImmunodeficiency virusART availabilitySurvival differencesSuppressive efficacyCohortPatientsTherapyTotal numberRetention ratePersonsBenefits
2011
Resource Utilization and Cost-Effectiveness of Counselor- vs. Provider-Based Rapid Point-of-Care HIV Screening in the Emergency Department
Walensky RP, Morris BL, Reichmann WM, Paltiel AD, Arbelaez C, Donnell-Fink L, Katz JN, Losina E. Resource Utilization and Cost-Effectiveness of Counselor- vs. Provider-Based Rapid Point-of-Care HIV Screening in the Emergency Department. PLOS ONE 2011, 6: e25575. PMID: 22022415, PMCID: PMC3192047, DOI: 10.1371/journal.pone.0025575.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsIncremental cost-effectiveness ratioUndiagnosed HIV prevalenceEmergency department settingCost-effectiveness ratioHIV prevalenceDepartment settingScreening modalityRandomized clinical trialsResource utilization dataRoutine HIVHIV screeningHIV counselorsEmergency departmentScreening servicesClinical trialsCapacity of providersScreening programED staffHIVTest offerLife yearsUtilization dataRapid pointPrevalence
2009
Racial and Sex Disparities in Life Expectancy Losses among HIV-Infected Persons in the United States: Impact of Risk Behavior, Late Initiation, and Early Discontinuation of Antiretroviral Therapy
Losina E, Schackman BR, Sadownik SN, Gebo KA, Walensky RP, Chiosi JJ, Weinstein MC, Hicks PL, Aaronson WH, Moore RD, Paltiel AD, Freedberg KA. Racial and Sex Disparities in Life Expectancy Losses among HIV-Infected Persons in the United States: Impact of Risk Behavior, Late Initiation, and Early Discontinuation of Antiretroviral Therapy. Clinical Infectious Diseases 2009, 49: 1570-1578. PMID: 19845472, PMCID: PMC2783631, DOI: 10.1086/644772.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveFemaleHIV InfectionsHumansLife ExpectancyMalePatient ComplianceRacial GroupsRisk-TakingSex FactorsSurvival AnalysisUnited StatesConceptsEarly discontinuationHIV infectionAntiretroviral therapyYears of lifeLate initiationRisk behaviorsLate presentationHuman immunodeficiency virus (HIV) infectionHIV Research NetworkLate treatment initiationCohort of HIVImmunodeficiency virus infectionLife expectancyStandardized mortality ratioGeneral US populationHigh-risk profileYears of ageHigh-risk behaviorsSimilar demographic characteristicsRace/ethnicityART discontinuationART initiationCare concordantHispanic HIVAdvanced diseaseCost-Effectiveness of Preventing Loss to Follow-up in HIV Treatment Programs: A Côte d'Ivoire Appraisal
Losina E, Touré H, Uhler LM, Anglaret X, Paltiel AD, Balestre E, Walensky RP, Messou E, Weinstein MC, Dabis F, Freedberg KA, AIDS F, investigators A. Cost-Effectiveness of Preventing Loss to Follow-up in HIV Treatment Programs: A Côte d'Ivoire Appraisal. PLOS Medicine 2009, 6: e1000173. PMID: 19859538, PMCID: PMC2762030, DOI: 10.1371/journal.pmed.1000173.Peer-Reviewed Original ResearchMeSH KeywordsAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveCost-Benefit AnalysisCote d'IvoireDeveloping CountriesFollow-Up StudiesHealth Care CostsHIV InfectionsHumansLife ExpectancyTreatment OutcomeConceptsHIV treatment programsResource-limited settingsPerson/yearART initiationAIDS Complications-International modelTreatment programWorld Health Organization criteriaAntiretroviral therapy initiationLTFU ratesHIV careTherapy initiationCumulative incidenceClinical benefitOrganization criteriaClinical impactLTFUPayer perspectiveCost of interventionInternational criteriaLife expectancyEfficacyInterventionPreventing LossCareSurvival loss
2008
Scaling Up Antiretroviral Therapy in South Africa: The Impact of Speed on Survival
Walensky RP, Wood R, Weinstein MC, Martinson NA, Losina E, Fofana MO, Goldie SJ, Divi N, Yazdanpanah Y, Wang B, Paltiel AD, Freedberg KA. Scaling Up Antiretroviral Therapy in South Africa: The Impact of Speed on Survival. The Journal Of Infectious Diseases 2008, 197: 1324-1332. PMID: 18422445, PMCID: PMC2423492, DOI: 10.1086/587184.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAnti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveCohort StudiesHIV InfectionsHumansModels, BiologicalSouth AfricaConceptsAntiretroviral therapyEligible human immunodeficiency virusEffective antiretroviral therapyHuman immunodeficiency virusNeed of therapyHIV infectionImmunodeficiency virusPatient outcomesAdult cohortDeath rateART scaleTherapyCumulative deathsTreatment slotsDeathRapid scaleHIVPatientsCohortInfectionMortality
2005
Expanded Screening for HIV in the United States — An Analysis of Cost-Effectiveness
Paltiel AD, Weinstein MC, Kimmel AD, Seage GR, Losina E, Zhang H, Freedberg KA, Walensky RP. Expanded Screening for HIV in the United States — An Analysis of Cost-Effectiveness. New England Journal Of Medicine 2005, 352: 586-595. PMID: 15703423, DOI: 10.1056/nejmsa042088.Peer-Reviewed Original ResearchConceptsOne-time screeningEnzyme-linked immunosorbent assayGeneral populationHuman immunodeficiency virus (HIV) infectionRoutine HIV counselingEffective antiretroviral therapyImmunodeficiency virus infectionLow-risk populationHigh-risk populationQuality-adjusted survivalCost-effectiveness ratioU.S. general populationAverage survival timeCDC thresholdAntiretroviral therapyHIV screeningHIV antibodiesObservational cohortHIV counselingClinical trialsCost-effectiveness groundsVirus infectionEarly diagnosisVoluntary screeningSurvival time
2003
Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection
Goldie SJ, Paltiel AD, Weinstein MC, Losina E, Seage GR, Kimmel AD, Walensky RP, Sax PE, Freedberg KA. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. The American Journal Of Medicine 2003, 115: 632-641. PMID: 14656616, DOI: 10.1016/j.amjmed.2003.07.007.Peer-Reviewed Original ResearchMeSH KeywordsAntiretroviral Therapy, Highly ActiveCohort StudiesCost-Benefit AnalysisHIV InfectionsHumansLife ExpectancyModels, TheoreticalOutcome and Process Assessment, Health CarePatient ComplianceUrban PopulationConceptsQuality-adjusted life expectancyHuman immunodeficiency virus (HIV) infectionClinical trial cohortImmunodeficiency virus infectionAdvanced diseaseCost-effectiveness ratioAdherence interventionsAntiretroviral therapyTrial cohortEarly diseaseVirus infectionUrban cohortLife expectancyHIV ribonucleic acid levelsEffective adherence interventionsCD4 cell countCombination antiretroviral therapyVirologic failure ratesLow baseline levelsFailure rateRibonucleic acid levelsStandard careHIV infectionHealthy patientsClinical trials
2002
Prevention of Human Immunodeficiency Virus—Related Opportunistic Infections in France: A Cost-Effectiveness Analysis
Yazdanpanah Y, Goldie S, Paltiel A, Losina E, Coudeville L, Weinstein M, Gerard Y, Kimmel A, Zhang H, Salamon R, Mouton Y, Freedberg K. Prevention of Human Immunodeficiency Virus—Related Opportunistic Infections in France: A Cost-Effectiveness Analysis. Clinical Infectious Diseases 2002, 36: 86-96. PMID: 12491207, DOI: 10.1086/344902.Peer-Reviewed Original ResearchMeSH KeywordsAIDS-Related Opportunistic InfectionsAntiretroviral Therapy, Highly ActiveChemopreventionCost-Benefit AnalysisFranceGuidelines as TopicHIV InfectionsHumansLife ExpectancyQuality of LifeConceptsCost-effectiveness ratioTMP-SMZAntiretroviral therapyHIV diseaseOpportunistic infectionsHuman immunodeficiency virus (HIV) diseaseMycobacterium avium complex bacteremiaIncremental cost-effectiveness ratioPerson lifetime costsActive antiretroviral therapyEra of HAARTPneumocystis carinii pneumoniaHuman immunodeficiency virusQuality-adjusted life expectancyCost-effectiveness analysisOral ganciclovirCytomegalovirus infectionToxoplasmic encephalitisCarinii pneumoniaImmunodeficiency virusTherapeutic optionsClinical impactFrench patientsProphylaxisInfectionLifetime Cost of HIV Care in France during the Era of Highly Active Antiretroviral Therapy
Yazdanpanah Y, Goldie SJ, Losina E, Weinstein MC, Lebrun T, Paltiel AD, Seage GR, Leblanc G, Ajana F, Kimmel AD, Zhang H, Salamon R, Mouton Y, Freedberg KA. Lifetime Cost of HIV Care in France during the Era of Highly Active Antiretroviral Therapy. Antiviral Therapy 2002, 7: 257-266. PMID: 12553480, DOI: 10.1177/135965350200700405.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountCohort StudiesFranceHealth Care CostsHIV InfectionsHumansMiddle AgedConceptsActive antiretroviral therapyHIV infectionCD4 strataAntiretroviral therapyHIV careHIV diseaseLifetime costsHighly Active Antiretroviral TherapyHigher CD4 strataHIV Clinical CohortLowest CD4 stratumCD4 cell countEra of HAARTBurden of diseaseStage of illnessCost of careHealth policy plannersHealth care costsClinical managementSpecific AIDSClinical cohortMean costFrench patientsCare costsCell count